Sarracenia purpurea, the purple pitcher plant, is a carnivorous bog plant native to eastern North America that has a long history of medicinal use. Indigenous communities traditionally prepared it as a remedy for smallpox, lung and liver complaints, fever, and digestive issues. Modern laboratory research has confirmed some of these traditional applications, particularly its antiviral activity against poxviruses, and newer studies are exploring its potential effects on cancer cells.
Traditional Medicinal Uses
Indigenous peoples of North America were the first to use Sarracenia purpurea medicinally. Tea brewed from dried foliage served as a treatment for fever and colds. The roots were consumed as a remedy for lung disease, liver problems, and smallpox. The plant was also used as a diuretic and as a traditional remedy during childbirth.
Its reputation as a smallpox treatment is what eventually drew scientific attention. During the 19th century, accounts of Indigenous communities using pitcher plant preparations against smallpox reached European and colonial physicians, sparking curiosity that would take more than a century to investigate in a laboratory setting.
Antiviral Activity Against Poxviruses
The most rigorously studied use of Sarracenia purpurea is its ability to block poxvirus replication. Researchers at Arizona State University confirmed in laboratory experiments that extracts of the plant shut down an early and essential step in the virus’s life cycle: the transcription of viral genes. Without this step, the virus cannot produce the proteins it needs to multiply inside a host cell.
In cell cultures, the extract prevented the virus from accumulating early proteins after it had already entered the cell. As researchers increased the concentration of the extract, viral gene transcription dropped proportionally while untreated cells showed normal levels. This made Sarracenia purpurea the first identified compound to target poxviruses specifically at this early transcription stage, a mechanism distinct from other antiviral drugs.
These results are significant because effective treatments for poxviruses remain limited. While smallpox was eradicated through vaccination, related viruses like monkeypox still pose threats, and bioterrorism concerns keep poxvirus research active. The pitcher plant’s mechanism of action could inform new antiviral strategies, though the work so far has been done only in lab dishes, not in people.
Laboratory Research on Cancer Cells
A 2025 study published in the journal Plants tested an extract from the plant’s roots against three types of human non-small-cell lung cancer cells. The root extract, prepared using acetone, proved to be the most potent fraction of the plant. It killed cancer cells in a dose-dependent manner, meaning higher concentrations produced stronger effects. The most sensitive cancer cell line showed 100% cell death at certain concentrations, while the least sensitive still reached roughly 92% cell death.
Beyond simply killing cells, the extract blocked two behaviors that make cancer dangerous: migration and colony formation. In wound-healing tests that measure how quickly cancer cells spread across a surface, the extract at moderate-to-high concentrations stopped cell movement almost entirely. Colony formation, which reflects a cancer cell’s ability to establish new growths, dropped by 85% to 100% depending on the cell line and dose.
The researchers also found that the root extract interfered with a specific protein that cancer cells rely on to repair their DNA and keep dividing. When combined with an existing targeted cancer drug, the extract appeared to enhance the drug’s effects. All of this remains in the early, cell-culture stage of research, far from any clinical application, but it suggests the plant contains compounds worth investigating further.
Active Compounds in the Plant
Chemical analysis of Sarracenia purpurea leaves has identified a range of biologically active substances. Researchers isolated several phenolic compounds and goodyerosides from leaves collected in Quebec, Canada. Betulinic acid and ursolic acid, two compounds known for their anti-inflammatory and cell-protective properties in other plants, have also been extracted from the species. The plant additionally contains a compound called morroniside, which appears in several other medicinal plant species. The specific compound or combination of compounds responsible for the antiviral and anticancer effects has not yet been pinpointed.
Safety and Dosage
There is very little formal safety data on Sarracenia purpurea. The side effects of taking it by mouth are not well documented, and no regulatory body has established a recommended dosage range. The U.S. FDA has not approved any medicinal use of the plant. An injectable form that existed historically was noted to cause warmth at the injection site, but injectable preparations are not commercially available today.
Because herbal products made from pitcher plant are unregulated, quality can vary significantly between products. Some herbal supplements in general have been found to contain contaminants, including toxic metals or undisclosed drugs. If you encounter pitcher plant products sold as supplements or tinctures, there is no standardized dose backed by clinical evidence to guide safe use.
Conservation Concerns
Sarracenia purpurea grows in nutrient-poor bogs and wetlands across eastern North America. While the species as a whole is not federally listed as endangered, at least one variety, the mountain purple pitcher plant found in the southeastern United States, is under review for potential listing as endangered or threatened. Wetland drainage, habitat loss, and overharvesting all threaten wild populations. Anyone interested in the plant for medicinal, gardening, or research purposes should source it from cultivated stock rather than wild populations. Many carnivorous plant nurseries propagate the species commercially, reducing pressure on wild stands.